NO20005632L - Antistoffer mot CD23, derivater derav og deres terapeutiske anvendelse - Google Patents

Antistoffer mot CD23, derivater derav og deres terapeutiske anvendelse

Info

Publication number
NO20005632L
NO20005632L NO20005632A NO20005632A NO20005632L NO 20005632 L NO20005632 L NO 20005632L NO 20005632 A NO20005632 A NO 20005632A NO 20005632 A NO20005632 A NO 20005632A NO 20005632 L NO20005632 L NO 20005632L
Authority
NO
Norway
Prior art keywords
antibodies
derivatives
therapeutic use
therapeutic
Prior art date
Application number
NO20005632A
Other languages
English (en)
Norwegian (no)
Other versions
NO20005632D0 (no
Inventor
Jean-Yves Marcel Paul Bonnefoy
Scott James Crowe
Jonathan Henry Ellis
Nicholas Timothy Rapson
Jean Shearin
Original Assignee
Glaxo Wellcome Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome Ltd filed Critical Glaxo Wellcome Ltd
Publication of NO20005632D0 publication Critical patent/NO20005632D0/no
Publication of NO20005632L publication Critical patent/NO20005632L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO20005632A 1998-05-09 2000-11-08 Antistoffer mot CD23, derivater derav og deres terapeutiske anvendelse NO20005632L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9809839.5A GB9809839D0 (en) 1998-05-09 1998-05-09 Antibody
PCT/GB1999/001434 WO1999058679A1 (en) 1998-05-09 1999-05-07 Antibodies to cd23, derivatives thereof, and their therapeutic uses

Publications (2)

Publication Number Publication Date
NO20005632D0 NO20005632D0 (no) 2000-11-08
NO20005632L true NO20005632L (no) 2001-01-08

Family

ID=10831668

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20005632A NO20005632L (no) 1998-05-09 2000-11-08 Antistoffer mot CD23, derivater derav og deres terapeutiske anvendelse

Country Status (25)

Country Link
US (1) US7008623B1 (is)
EP (1) EP1076701A1 (is)
JP (1) JP2002514421A (is)
KR (1) KR20010043470A (is)
CN (1) CN1308676A (is)
AP (1) AP1547A (is)
AU (1) AU763491B2 (is)
BR (1) BR9910327A (is)
CA (1) CA2328606A1 (is)
EA (1) EA200001041A1 (is)
EE (1) EE200000658A (is)
GB (1) GB9809839D0 (is)
HR (1) HRP20000762A2 (is)
HU (1) HUP0102005A3 (is)
ID (1) ID28088A (is)
IL (1) IL139384A0 (is)
IS (1) IS5696A (is)
NO (1) NO20005632L (is)
NZ (1) NZ507879A (is)
PL (1) PL344019A1 (is)
SK (1) SK16762000A3 (is)
TR (1) TR200003281T2 (is)
WO (1) WO1999058679A1 (is)
YU (1) YU69000A (is)
ZA (1) ZA200006312B (is)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696550B2 (en) 1998-07-23 2004-02-24 Millennium Pharmaceuticals, Inc. Humanized anti-CCR2 antibodies and methods of use therefor
EE200300179A (et) 2000-10-13 2003-08-15 Biogen, Inc. Humaniseeritud LT-ß-R-i vastased antikehad
US20040151721A1 (en) 2001-10-19 2004-08-05 O'keefe Theresa Humanized anti-CCR2 antibodies and methods of use therefor
CA2491480A1 (en) * 2002-07-01 2004-01-08 Biogen, Inc. Humanized anti-lymphotoxin beta receptor antibodies
TWI323265B (en) 2002-08-06 2010-04-11 Glaxo Group Ltd Antibodies
GB0306309D0 (en) 2003-03-19 2003-04-23 Glaxo Group Ltd Method of treatment
US20050163782A1 (en) 2003-06-27 2005-07-28 Biogen Idec Ma Inc. Modified binding molecules comprising connecting peptides
CA2434668A1 (en) 2003-07-04 2005-01-04 Laurence Mulard Novel approach to design glycopeptides based on o-specific polysaccharide of shigella flexneri serotype 2a
EP2135619A1 (en) * 2003-12-10 2009-12-23 Millennium Pharmaceuticals, Inc. Humanized anti-CCR2 antibodies and methods of use therefor
US7435799B2 (en) * 2004-01-08 2008-10-14 Applied Molecular Evolution TNF-α binding molecules
SG151294A1 (en) 2004-03-23 2009-04-30 Biogen Idec Inc Receptor coupling agents and therapeutic uses thereof
WO2006039470A2 (en) * 2004-09-29 2006-04-13 Centocor, Inc. Anti- amyloid antibodies, compositions, methods and uses
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
JP5123197B2 (ja) 2005-11-14 2013-01-16 ライナット ニューロサイエンス コーポレイション カルシトニン遺伝子関連ペプチドに対するアンタゴニスト抗体およびその使用方法
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
US7680868B2 (en) * 2005-12-20 2010-03-16 Roche Molecular Systems, Inc. PCR elbow determination by use of a double sigmoid function curve fit with the Levenburg-Marquardt algorithm and normalization
EP1804172B1 (en) * 2005-12-20 2021-08-11 Roche Diagnostics GmbH PCR elbow determination using curvature analysis of a double sigmoid
US20090155255A1 (en) * 2007-09-27 2009-06-18 Biogen Idec Ma Inc. Cd23 binding molecules and methods of use thereof
EP2641919A3 (en) 2007-11-30 2014-05-07 Glaxo Group Limited Antigen-binding constructs
JP5537441B2 (ja) 2008-03-04 2014-07-02 ファイザー・リミテッド 慢性疼痛を治療する方法
AR072359A1 (es) 2008-05-06 2010-08-25 Glaxo Group Ltd Encapsulacion de agentes biologicamente activos
WO2010097386A1 (en) 2009-02-24 2010-09-02 Glaxo Group Limited Antigen-binding constructs
CA2753287A1 (en) 2009-02-24 2010-09-02 Glaxo Group Limited Antigen-binding constructs
EP2401296A1 (en) 2009-02-24 2012-01-04 Glaxo Group Limited Multivalent and/or multispecific rankl-binding constructs
CA2757237A1 (en) 2009-04-01 2010-10-14 Jane Elizabeth Clarkson Anti-il-23 immunoglobulins
US20120058116A1 (en) 2009-04-24 2012-03-08 Andrew Beaton Fgfr1c antibody combinations
KR101519192B1 (ko) 2009-08-28 2015-05-11 리나트 뉴로사이언스 코프. 칼시토닌 유전자-관련된 펩티드에 대해 지시된 길항제 항체의 투여에 의한 내장 통증의 치료 방법
FR2957598B1 (fr) 2010-03-17 2015-12-04 Lfb Biotechnologies Nouveau peptide signal, et son utilisation pour la production de proteines recombinantes
WO2012069433A2 (en) 2010-11-23 2012-05-31 Glaxo Group Limited Antigen binding proteins
JP2014501725A (ja) 2010-11-24 2014-01-23 グラクソ グループ リミテッド Ｈｇｆを標的とする多特異的抗原結合タンパク質
US8974782B2 (en) 2011-02-07 2015-03-10 Glaxo Group Limited Treatment of stroke comprising anti-MAG antibodies
SG194176A1 (en) 2011-05-27 2013-12-30 Glaxo Group Ltd Bcma (cd269/tnfrsf17) -binding proteins
EP2888279A1 (en) 2012-08-22 2015-07-01 Glaxo Group Limited Anti lrp6 antibodies
US10176293B2 (en) 2012-10-02 2019-01-08 Roche Molecular Systems, Inc. Universal method to determine real-time PCR cycle threshold values
HRP20201113T1 (hr) 2013-03-15 2020-10-30 Glaxosmithkline Intellectual Property Development Limited Vežući proteini protiv lag-3
CA2917661C (en) * 2013-07-10 2023-09-12 Onconox Aps Antibodies to .beta.2-glycoprotein i and therapeutic uses thereof
HRP20240159T1 (hr) 2014-03-21 2024-04-12 Teva Pharmaceuticals International Gmbh Antagonistička protutijela usmjerena protiv peptida povezanog s genom kalcitonina i postupci koji ih koriste
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
RU2021133819A (ru) 2015-09-02 2021-12-10 Иммутеп С.A.С. Анти-lag-3 антитела
JP6935184B2 (ja) * 2016-05-31 2021-09-15 シスメックス株式会社 糖ペプチドと反応するモノクローナル抗体およびその用途
US10479827B2 (en) * 2016-05-31 2019-11-19 Sysmex Corporation Monoclonal antibody reacting with glycopeptide, and use thereof
TWI640536B (zh) 2016-06-20 2018-11-11 克馬伯有限公司 抗體
KR20220031944A (ko) 2016-09-23 2022-03-14 테바 파마슈티컬스 인터내셔널 게엠베하 불응성 편두통의 치료
JP7355742B2 (ja) 2018-01-18 2023-10-03 フレッド ハッチンソン キャンサー センター 細胞活性状態を調節することにより免疫細胞の炎症状態をインビボで変更すること
TWI905099B (zh) 2019-05-21 2025-11-21 瑞士商諾華公司 Cd19 結合分子及其用途
MA56397A (fr) 2019-06-26 2022-05-04 Glaxosmithkline Ip Dev Ltd Protéines de liaison à l'il1rap
CN112552403A (zh) * 2020-12-25 2021-03-26 南京英瀚斯生物科技有限公司 一种人源抗人CD23抗体的Fab片段、药物组合物及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9204374A (es) * 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
BR9206313A (pt) * 1991-07-25 1995-04-11 Idec Pharma Corp Anticorpos recombinantes para terapia humana.
US6627195B1 (en) * 1994-10-25 2003-09-30 Smithkline Beecham Corporation Binding agents to CD23
US6011138A (en) * 1997-02-20 2000-01-04 Idec Pharmaceuticals Corporation Gamma-1 anti-human CD23 monoclonal antibodies

Also Published As

Publication number Publication date
JP2002514421A (ja) 2002-05-21
NZ507879A (en) 2004-02-27
CA2328606A1 (en) 1999-11-18
US7008623B1 (en) 2006-03-07
HRP20000762A2 (en) 2001-06-30
SK16762000A3 (sk) 2001-07-10
WO1999058679A1 (en) 1999-11-18
BR9910327A (pt) 2001-01-30
GB9809839D0 (en) 1998-07-08
HUP0102005A2 (hu) 2001-10-28
AU3836799A (en) 1999-11-29
EE200000658A (et) 2002-04-15
PL344019A1 (en) 2001-09-24
KR20010043470A (ko) 2001-05-25
AP2000001983A0 (en) 2000-12-31
HUP0102005A3 (en) 2003-10-28
CN1308676A (zh) 2001-08-15
ID28088A (id) 2001-05-03
TR200003281T2 (tr) 2001-03-21
EP1076701A1 (en) 2001-02-21
IL139384A0 (en) 2001-11-25
ZA200006312B (en) 2003-02-26
IS5696A (is) 2000-10-31
YU69000A (sh) 2003-08-29
AP1547A (en) 2006-01-13
NO20005632D0 (no) 2000-11-08
EA200001041A1 (ru) 2001-06-25
AU763491B2 (en) 2003-07-24

Similar Documents

Publication Publication Date Title
NO20005632L (no) Antistoffer mot CD23, derivater derav og deres terapeutiske anvendelse
DK0869126T3 (da) Dithiolanderivater, deres fremstilling og deres terapeutiske virkning
NO20015156L (no) 5-pyridyl-1,3-azolforbindelser, deres fremstilling og anvendelse
NO20014603D0 (no) Tienopyrimidinforbindelser, deres fremstilling og anvendelse
NO20021449L (no) Substituerte 2-tio-3,5-dicyano-4-aryl-6-aminopyridiner og deres anvendelse
NO961160D0 (no) Cykliske forbindelser, deres fremstilling og anvendelse
NO20003067D0 (no) Antipicornavirus-forbindelser og fremgangsmÕter for deres anvendelse og fremstilling
NO980720D0 (no) Pyridazin-3-on-derivater, deres anvendelse og mellomprodukter for deres fremstilling
DK1161434T3 (da) Pyridopyranoazepinderivater, deres fremstilling og terapeutiske anvendelse
DK1073672T3 (da) Antipicornavirale forbindelser, deres fremstilling og anvendelse
NO943682D0 (no) Imidazol-4-yl-piperidin-derivater, deres fremstilling og terapeutiske anvendelse
DK1043307T3 (da) 3-amino-3-arylpropan-1-ol-derivater, deres fremstilling og anvendelse
NO20003734L (no) Heteroarylsubstituerte pyrrolderivater, deres fremstilling og deres terapeutiske anvendelser
NO20001934D0 (no) 3-Substituerte tetrahydropyridopyrimidinon-derivater, deres fremstilling og anvendelse
NO962477L (no) Benzamidderivater, deres fremstilling og deres terapautiske anvendelse
NO20013085D0 (no) Fosfororganiske forbindelser og deres anvendelse
PT1178981E (pt) 3-piridil-4-arilpirrois substituidos e metodos terapeuticos e profilacticos
NO20030547L (no) Azabicykliske derivater og deres terapeutiske anvendelse
NO20024107L (no) Tienopyridin derivater, deres fremstilling og anvendelse
NO20000066D0 (no) 6-pyrrolidin-2-ylpyrindin-derivater, deres fremstilling og deres farmasoeytiske anvendelse
NO20006479D0 (no) Tienopyridinforbindelser, deres fremstilling og anvendelse
NO955242D0 (no) Piperidinderivater, fremgangsmåte for fremstilling derav og deres terapeutiske anvendelse
NO20001782D0 (no) 3-amino-3-arylpropan-1-ol-derivater, deres fremstilling og anvendelse
NO996156L (no) Substituerte cykloheptener, deres fremstilling og anvendelse
NO950560D0 (no) Piperazinderivater, deres fremstilling og terapautiske anvendelse

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application